Install
A stock market site by Business Insider with real-time data, custom charts and breaking news. Get the latest on stocks, commodities, currencies, funds, rates, ETFs, and more.
- 31,386articles · 365d
- 4+ hour agolatest article
- Sep 14, 2025earliest in window
- 93%with images
- 290avg words
- business 12,845
- globenewswire 9,792
- tmt newswire 9,624
- technology 7,600
- stocks 7,514
- companies 6,237
- finanzen 6,123
- artificial intelligence 5,860
- markets 5,543
- finance 4,453
- ai 4,132
- business news 3,489
- health 3,296
- sec filings 3,076
- 13f 2,951
- blockchain 2,900
- hedge fund holdings 2,886
- cryptocurrency 2,845
- stock 2,801
- bitcoin 2,623
- Economy, Business & Finance 26,602
- Finance & Business 22,238
- News 10,076
- Finance 4,949
- Business & Industrial 4,919
- Health & Wellness 3,722
- Medical 2,567
- Computers & Electronics 1,147
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
3+ mon, 3+ week ago (263+ words) Important Safety Information for IMPAVIDO ® IMPAVIDO® is an antileishmanial drug indicated in adults and pediatric 12 years of age and older weighing greater than or equal to 30 kg (66 lbs) for treatment of: Limitations of use: Leishmania species evaluated in clinical trials…...
Pyxis Oncology to Participate in Upcoming Investor Conferences
4+ mon, 16+ hour ago (208+ words) Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following... Pyxis Oncology to Participate in Upcoming Investor Conferences BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS),…...
SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026
4+ mon, 1+ week ago (256+ words) SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be... SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026 SANTA CLARA, Calif., April…...
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
4+ mon, 1+ week ago (834+ words) AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer’s disease The safety and tolerability profile of AUVELITY in agitation associated with dementia due to Alzheimer’s disease has been…...
Denovo Announces Issuance of U.S. Patent of Novel Genetic Biomarker ANK3 (DGM4™) for Liafensine (DB104)
4+ mon, 2+ week ago (502+ words) Denovo Biopharma, a pioneer in applying precision medicine in central nervous system (CNS) diseases, today announced that the U.S. Patent and Trademark Office issued U.S. patent number 12,612,261,... Denovo Announces Issuance of U.S. Patent of Novel Genetic Biomarker ANK3 (DGM4™) for Liafensine (DB104) SAN DIEGO, April 29, 2026 (GLOBE…...
Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder
9+ mon, 1+ week ago (420+ words) Vancouver, Canada, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and... Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical…...
Kestra Medical Technologies to Present at the BofA Securities 2026 Healthcare Conference
4+ mon, 2+ week ago (107+ words) Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, is scheduled to present at the BofA Securities 2026 Healthcare Conference on... Kestra Medical Technologies to Present at the BofA Securities 2026 Healthcare Conference KIRKLAND, Wash., April…...
Dentsply Sirona to Host First Quarter 2026 Conference Call on May 5
4+ mon, 3+ week ago (169+ words) A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call. Dentsply Sirona is the world’s largest diversified manufacturer of... Dentsply Sirona to Host First Quarter 2026 Conference Call on May…...
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
4+ mon, 3+ week ago (231+ words) Expansion Adds to Growing Global Trial FootprintPatient Screening and Enrollment Expected to Begin in Q2 2026SOUTH SAN FRANCISCO, Calif., April 2... Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia - Patient Screening and Enrollment Expected to Begin in Q2 2026 SOUTH SAN FRANCISCO,…...
Soleo Health Expands Rare Disease Capabilities With Launch of SoleoRare™, A Specialty Pharmacy Focused on Complex Patient Needs
4+ mon, 3+ week ago (394+ words) markets.businessinsider.com Soleo Health Expands Rare Disease Capabilities With Launch of SoleoRare™, A Specialty Pharmacy Focused on Complex Patient Needs FRISCO, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, today…...